Emma Moatt
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 7
-
- Fibromyalgia and Chronic Fatigue Syndrome Research 1
- Co-authors
- Michael Ross Backhouse (1 shared paper)Christina Maria Van Der Feltz-Cornelis (1 shared paper)
- Journals
- The Lancet (6 papers)Primary Health Care Research & Development (1 paper)Nature Communications (1 paper)The Lancet Child & Adolescent Health (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Emma Moatt
9 papers receiving 1.6k citations
Emma Moatt's Hit Papers
Peers
Comparison fields: 5 of 82
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Statistics and Probability 46
- Oncology 75
Countries citing papers authored by Emma Moatt
This map shows the geographic impact of Emma Moatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Moatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Moatt more than expected).
Fields of papers citing papers by Emma Moatt
This network shows the impact of papers produced by Emma Moatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Moatt. The network helps show where Emma Moatt may publish in the future.
Co-authors
The 2 scholars most cited alongside Emma Moatt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2024 | 24 | |
| 8 | 2023 | 21 | |
| 9 | 2024 | 6 |
About Emma Moatt
Emma Moatt is a scholar working on Infectious Diseases, Psychiatry and Mental health, General Health Professions, Surgery and Nuclear Energy and Engineering, having authored 9 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Patient-Provider Communication in Healthcare (1 paper), Kawasaki Disease and Coronary Complications (1 paper) and Fibromyalgia and Chronic Fatigue Syndrome Research (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Statistics and Probability (46 citations) and Oncology (75 citations). Emma Moatt has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Michael Ross Backhouse and Christina Maria Van Der Feltz-Cornelis. Their work appears in journals such as The Lancet, Primary Health Care Research & Development, Nature Communications and The Lancet Child & Adolescent Health.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.